Ovarian Cancer Treatment — Are We Getting Warmer?
Mené sur 245 patientes atteintes d'un cancer épithélial de l'ovaire de stade III et ayant reçu une chimiothérapie néoadjuvante par carboplatine, cet essai de phase III évalue, du point de vue de la survie sans récidive, l'intérêt d'ajouter une chimiothérapie hyperthermique intrapéritonéale à une chirurgie cytoréductive
Regional chemotherapy theoretically results in a decreased rate of systemic toxic effects and a high pharmacologic advantage in tumors that are confined to a single organ or body cavity.1 However, only in the case of ovarian cancer has such chemotherapy (intraperitoneal chemotherapy) been accepted as part of the standard of care.2 Hyperthermia, at temperatures of up to 42.0°C (107.6°F), has also been considered to be a potential strategy for enhancing the chemotherapeutic effect but has not been widely accepted as part of routine cancer care. Previous uncontrolled trials in which hyperthermia was used in combination with intraperitoneal chemotherapy showed improved . . .
New England Journal of Medicine , éditorial, 2018